There are currently no treatment options available in the US specifically developed and approved for the treatment of CHE.
CHE is defined as hand eczema that lasts for more than three months or relapsing twice or more within a year.
HE is the most common skin disorder of the hands that affects an estimated 5% of the general population8 with a one-year prevalence rate of approximately 10%.
It is an inflammatory, non-infectious skin disorder of the hands and wrists and can cause itching, blisters, swelling and pain so severe that it can impair the ability to work.
In a substantial number of patients, HE can develop into a chronic condition.
There is an unmet need for well-tolerated, effective and safe treatments for long-term control of CHE.
Delgocitinib inhibits activation of the JAK-STAT pathway, which plays a key role in the immune system in driving the pathophysiology of chronic inflammatory skin diseases.
The cream formulation of delgocitinib is not currently approved by any regulatory authorities.
The FDA Fast Track process facilitates the development and expedites regulatory review of drugs to treat serious conditions and demonstrate the potential to address an unmet medical need.
According to the FDA, filling an unmet medical need is defined as 'providing a therapy where none exists or providing a therapy which may be potentially better than available therapy'.
The frequency of communication during the FDA Fast Track process allows for questions to be addressed quickly, often leading to earlier drug approval and access by patients.
In 2014, LEO Pharma A/S and Japan Tobacco Inc. entered into a license agreement in which LEO Pharma gained exclusive rights to develop and commercialise delgocitinib for topical use in dermatological indications worldwide, excluding Japan, where JT retains rights.
LEO Pharma recently completed a multi-center, randomized Phase 2b clinical trial with twice-daily topical delgocitinib cream for the treatment of adults with mild-to-severe CHE and a Phase 2b clinical trial with twice-daily topical delgocitinib cream for the treatment of adults with mild-to-severe atopic dermatitis.
LEO Pharma plans to submit the key results of the CHE Phase 2b study for publication later this year.
Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions.
LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92m patients in 130 countries.
NeoImmuneTech names new president and chief executive officer
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins